Anticancer research · 2026
Over-expression of Anillin Actin Binding Protein in Adrenocortical Carcinoma Tissues Is Associated With Poorer Prognosis of Patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yamashita Shin-Nosuke, Tanaka Yoshiatsu, Islam Shajedul, Kitagawa Takao, Tokuda Kazuhiro, Paudel Durga, Giri Sarita, Ohta Tohru, Harada Fumiya, Nagayasu Hiroki, Kuramitsu Yasuhiro
Аннотация
BACKGROUND/AIM: Adrenocortical carcinoma (ACC) is a rare adrenal cortex cancer (0.7-2.0 cases per million) with high malignancy and poor prognosis (5-year survival <40%). Early detection is difficult due to adrenal location, and effective treatments are lacking, highlighting the need for prognostic biomarkers and therapeutic targets. Anillin actin-binding protein (ANLN), a key regulator of cytokinesis, is overexpressed in many cancers compared with normal tissues and is associated with poor prognosis and advanced stage. However, the clinicopathological significance of ANLN in ACC remains unclear.
MATERIALS AND METHODS: ANLN mRNA expression and survival in patients with ACC [normal (n=128), stage I (n=9), stage II (n=37), stage III (n=16), stage IV (n=15)] were analyzed from TCGA database by using the UALCAN and GEPIA platforms, assessing ANLN mRNA expression across disease stages and its correlation with patient survival.
RESULTS: ANLN was found to be significantly increased in stage IV ACC tissues compared with stage I, II and III ACC tissues (p<0.05). Furthermore, increased expression was significantly correlated with poor patient prognosis (p<0.005).
CONCLUSION: ANLN may be a prognostic biomarker for patients with ACC and may play a role in tumor biology. Further studies are needed to determine whether ANLN is clinically useful as a prognostic factor in the treatment of ACC and to clarify its involvement in the mechanism of malignant progression of ACC.
MATERIALS AND METHODS: ANLN mRNA expression and survival in patients with ACC [normal (n=128), stage I (n=9), stage II (n=37), stage III (n=16), stage IV (n=15)] were analyzed from TCGA database by using the UALCAN and GEPIA platforms, assessing ANLN mRNA expression across disease stages and its correlation with patient survival.
RESULTS: ANLN was found to be significantly increased in stage IV ACC tissues compared with stage I, II and III ACC tissues (p<0.05). Furthermore, increased expression was significantly correlated with poor patient prognosis (p<0.005).
CONCLUSION: ANLN may be a prognostic biomarker for patients with ACC and may play a role in tumor biology. Further studies are needed to determine whether ANLN is clinically useful as a prognostic factor in the treatment of ACC and to clarify its involvement in the mechanism of malignant progression of ACC.